Cornerstone Therapeutics has launched Bethkis tobramycin inhalation solution for the treatment of cystic fibrosis patients with P. aeruginosa infections in the US, the company said. According to Cornerstone, one dose of Bethkis contains 300 mg of tobramycin in 4 mls of solution and can be delivered in about 15 minutes using a PARI LC Plus nebulizer.
The company also said that it is expanding its patient assistance program, which “provides reimbursement support and additional resources to help provide affordable access to treatment.”
Cornerstone CEO Craig A. Collard commented, “Cystic fibrosis patients have many challenges to navigate and we are pleased to be able to offer Bethkis as a management option for this chronic and debilitating condition.”
Bethkis was developed by Chiesi, and Cornerstone acquired the US license in 2012. In September 2013, Chiesi announced that it would acquire all outstanding shares of Cornerstone.
Read the Cornerstone press release.
